Novartis Pharma AG: Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
Pivotal results for efficacy and safety of Cosentyx (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology
Source: finanznachrichten.de